||Recombinant Human IGFBP3 (Accession # CAA46087) Gly28-Lys291, fused with an N-terminal Met, was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA.
||Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.The ED50 for this effect is typically 0.05 - 0.15 µg/mL in the presence of 14 ng/mL rhIGF-II.
||Recombinant Human IGFBP3, Met-tagged has a calculated MW of 29 kDa. In SDS-PAGE migrates as 41 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).